Evaluation of Safety and Efficacy of Anticoagulation Treatment in Patients With Splanchnic Vein Thrombosis: SAPIENT Study — SAPIENT

Splanchnic Vein Thrombosis Clinical Trial

Official title:
Evaluation of Safety and Efficacy of Anticoagulation Treatment in Patients With Splanchnic Vein Thrombosis: SAPIENT Study

Status Recruiting

Clinical Trial Summary

Prospective single-centre, observational study with medical products. Patients with a medical history of SVT will be observed for at least 24 months after inclusion. The study will begin when the patient is referred to our centre for SVT and will end at the 24-month follow-up or at the occurrence of a study outcome event, or in case of Death OBJECTIVE: To prospectively define the incidence of recurrent thrombosis and bleeding events during anticoagulant therapy in patients with diagnosed SVT, regardless of whether they will be hospitalized or treated as outpatients

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06262750
Study type	Observational
Source	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact	valerio de stefano
Phone	+390630154206
Email	valerio.destefano@unicatt.it
Status	Recruiting
Phase
Start date	December 1, 2023
Completion date	November 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04994158` - MASCOT Registry of Patients With Myeloproliferative Neoplasms Associated Splanchnic Vein Thrombosis
Recruiting	`NCT03778502` - DOAC in Unusual Site Venous Thrombosis
Active, not recruiting	`NCT04631458` - Outcomes in Patients With Myeloproliferative Neoplasm and Splanchnic Vein Thrombosis
Recruiting	`NCT06390475` - Optimizing Diagnosis of Splanchic Vein Thrombosis With MRDTI (Rhea)
Active, not recruiting	`NCT03080883` - Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy	Phase 3